News

EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering

Published on 2021-19-11

EyePoint Pharmaceuticals Ranked Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™

Published on 2021-18-11

EyePoint Pharmaceuticals Announces Pricing of Public Offering

Published on 2021-16-11

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Published on 2021-16-11

EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

Published on 2021-13-11

EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD

Published on 2021-05-11

EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Published on 2021-03-11

EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer

Published on 2021-01-11

EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting

Published on 2021-12-10

EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting

Published on 2021-17-09

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Published on 2021-07-09

EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference

Published on 2021-10-08

EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Published on 2021-04-08

EyePoint Pharmaceuticals Announces Renowned Scientists to Join New Executive Scientific Advisory Board

Published on 2021-02-08

EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021

Published on 2021-28-07

EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®

Published on 2021-20-07

EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD

Published on 2021-06-07

EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU^® Intraocular Suspension, Approved by the American Medical Association

Published on 2021-1-07

EyePoint Pharmaceuticals Joins Russell 2000^® and Russell 3000^® Index

Published on 2021-28-06

EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

Published on 2021-26-05

EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD

Published on 2021-25-05

EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Published on 2021-05-05

EyePoint Pharmaceuticals to Report First Quarter 2021 Financial Results and Discuss Recent Corporate Developments on May 5, 2021

Published on 2021-04-28

EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Corporate Developments

Published on 2021-03-04

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Published on 2021-02-25

EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

Published on 2021-02-25

EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock

Published on 2021-02-04

EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Published on 2021-02-01

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Published on 2021-02-01